Praluent ^*

Praluent (generic name: alirocumab) is a prescription medication classified as a PCSK9 inhibitor, a type of monoclonal antibody. It is designed to lower low-density lipoprotein cholesterol (LDL-C) levels in the blood. By binding to the PCSK9 protein, Praluent prevents the degradation of LDL receptors on liver cells, thereby enhancing the clearance of LDL-C from the bloodstream. Praluent is approved for use in adults with heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH), both genetic conditions characterized by high cholesterol levels. It is also indicated for patients with established cardiovascular disease to reduce the risk of heart attack, stroke, and unstable angina requiring hospitalization. Additionally, Praluent is used as an adjunct to diet and maximally tolerated statin therapy in patients who require additional LDL-C lowering.

Dosage

Praluent is administered by subcutaneous injection. Typically, the first dose is administered under the direction of the prescribing doctor in their office or consulting room. All subsequent doses must be taken exactly as prescribed. Praluent is administered via subcutaneous injection and is available in two dosing options:

• 75 mg every two weeks: This is the recommended starting dose.
• 300 mg every four weeks: An alternative dosing regimen for patients preferring monthly injections.

If the LDL-C response is inadequate, the dosage can be adjusted to 150 mg every two weeks. For patients with HoFH, the recommended dosage is 150 mg every two weeks. In pediatric patients aged 8 years and older with HeFH:

• Under 50 kg: 150 mg every four weeks; may adjust to 75 mg every two weeks if needed.
• 50 kg and over: 300 mg every four weeks; may adjust to 150 mg every two weeks if needed.

If a dose is missed in the fortnightly regimen, administer the missed dose as soon as possible if it is within 7 days; otherwise, skip the missed dose and resume the regular schedule. If a dose is missed during the four-week regimen, administer the missed dose as soon as possible if it is within 7 days; otherwise, inject the dose when remembered and start a new four-week schedule from that date.

Storage

Praluent should be stored in its original container under refrigeration at 36-46°F (2-8°C). If necessary, Praluent may be kept at room temperature below 77°F/25°C for a maximum of 30 days. Once removed from refrigeration, it should not be returned to the refrigerator and must be used within 30 days or discarded.

Common questions about Praluent

Can Praluent be used alone?

Praluent is usually used in combination with a healthy diet and maximally tolerated statin therapy. It is not typically used as a standalone treatment but may be considered in patients who cannot tolerate statins.

What is familial hypercholesterolemia?

Familial hypercholesterolemia is a genetic disorder characterized by high LDL-C levels, increasing the risk of early cardiovascular disease. It includes HeFH and HoFH, with HoFH being more severe.